A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor, in patients with advanced clear cell renal cell carcinoma.

Courtney, Kevin Dale, Infante, Jeffrey R., Lam, Elaine Tat · Journal of Clinical Oncology · 2016